Press release
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
– All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by
About this update from Vertex Pharmaceuticals Incorporated
[{"type":"text","content":"\n– All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90 –\n\n\n– All patients achieved ADA-recommended target HbA1c levels 70% time-in-range (70-180 mg/dL), and 11 of 12 patients reduced or eliminated use of exogenous insulin –\n\n\n- 3 patients with at least 12 months of follow-up, and therefore evaluable, met the primary endpoint of elimination of severe hypoglycemic events (SHEs) with HbA1c","length":721,"tagName":"div"}]